- Albany Molecular Research (AMRI) buys Cedarburg Pharmaceuticals, a contract developer and manufacturer of technically complex active pharmaceutical ingredients, for $41M.
- Cedarburg has provided development and manufacturing support for 13 FDA-approved products to date. Its 2014 revenue forecast is $19M with an adjusted EBITBA of ~$5.6M.
- 186 mutual funds have AMRI positions, up from 94 a year earlier.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at CNBC.com (Jan 9, 2015)
at MarketWatch.com (Oct 14, 2014)
at CNBC.com (Aug 15, 2014)
at MarketWatch.com (Dec 23, 2011)
at MarketWatch.com (May 20, 2011)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs